MARKET WIREReuters • 3h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why XTLB Stock dropped -12.44% Today — RQD Quant Desk Flash
$1.76 -12.44% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.72
XTL Biopharmaceuticals Ltd. (XTLB) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $4.3M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.72 (-2.43%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-5.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XTLB)Realized 20D OHLCV Swing Band: ±12.3%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY XTLB SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)
SEC XBRL Trailing 12 Months: 0% FCF Margin ($121.1K FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$1.98-1% Next Q
55
Q2 (-2Q)Grade C-$1.96+3.1% Next Q
52
Q3 (-1Q)Grade C-$2.02-12.9% Next Q
50
CurrentGrade D$1.76-5.9% Hist 90D α
47
Trajectory: C (55) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a XTLB Turnaround Squeeze
While XTLB currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.23) and Max Pain ($1.85) forces dealer call-delta covering toward $5.92.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $XTLB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “XTLB Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why XTLB Stock dropped -12.44% Today — RQD Quant Desk Flash
XTL Biopharmaceuticals Ltd. (XTLB) dropped -12.44% to $1.76, trading at 4% of its 52-week range ($1.6 – $5.64). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 4% of its 52-week range ($1.6 – $5.64) with RSI-14 at 33.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.3% around $1.76 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $121104 annual free cash flow.
Live XTLB Headlines & Catalysts
MARKET WIRECNBC • 5h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 5h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 7h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 8h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 9h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 9h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 10h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XTLB)
- ✓Walkthrough of XTLB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
XTLB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -54.87%▼ SUPPORT BREAKDOWN
2026-10-30O $1.65H $1.76L $1.60C $1.76VOL 8.6K
RES: $3.67SUP: $2.25SMA50: $2.23SMA200: $2.71
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
XTLB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on XTLB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for XTLB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for XTLB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XTLB)
Health Care Rank #431 of 1016
⚔️ NCNA vs XTLB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (XTLB vs. NCNA, DRMA, AZTR, MDCX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, XTL Biopharmaceuticals Ltd. (XTLB) ranks #431 by composite RQD confidence (47/100, grade D) and #957 by equity capitalization ($4.3M). Within this direct 5-issuer industry benchmark cohort, XTLB leads on earnings valuation at N/A trailing P/E, while DRMA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. NCNA currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with XTLB at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| XTLB
ACTIVE
XTL Biopharmaceuticals Ltd. | D | 47/100 | — | — | — | -12.44% | $4.3M | Benchmark Subject |
| NCNA NuCana plc | D+ | 56/100 | — | — | — | -3.26% | $4.3M | /ncna-vs-xtlb → |
| DRMA Dermata Therapeutics Inc. | D- | 43/100 | — | — | -35.0% | -3.84% | $4.2M | /drma-vs-xtlb → |
| AZTR Azitra Inc | D- | 41/100 | — | — | -35.0% | -16.31% | $4.6M | /aztr-vs-xtlb → |
| MDCX Medicus Pharma Ltd. | D- | 35/100 | — | — | -35.0% | -13.31% | $4.1M | /mdcx-vs-xtlb → |
2. XTLB Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTXTL Biopharmaceuticals Ltd. (XTLB) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $4.3M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. XTLB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs XTLB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.76 (-12.44% 1D, market cap $4.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, XTLB ranks #431 in composite RQD confidence.
How does XTLB compare to NCNA and DRMA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XTLB carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NCNA (NuCana plc) holds a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $4.3M) and DRMA (Dermata Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $4.2M). Among the 5-stock peer group, XTLB leads on earnings multiple (N/A) while DRMA leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for XTLB?
For XTL Biopharmaceuticals Ltd. (XTLB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #431 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is XTLB trading relative to its 50-day, 200-day, and 52-week technical levels?
XTLB last traded at $1.76 (-12.44% on volume of 7,065 shares), positioning the stock -21.08% below its 50-day simple moving average ($2.23) and -35.06% below its 200-day simple moving average ($2.71). Across its 52-week range of $1.60 to $5.64, XTLB sits at the 4.0% percentile with a 14-day RSI of 33.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.3% ($1.54 to $1.98).
XTLB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is XTLB stock moving today?
Why XTLB Stock dropped -12.44% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.